1. Home
  2. QBTS vs MOLN Comparison

QBTS vs MOLN Comparison

Compare QBTS & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo D-Wave Quantum Inc.

QBTS

D-Wave Quantum Inc.

HOLD

Current Price

$13.85

Market Cap

6.5B

Sector

Technology

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$4.05

Market Cap

158.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
QBTS
MOLN
Founded
1999
2004
Country
United States
Switzerland
Employees
388
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
158.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
QBTS
MOLN
Price
$13.85
$4.05
Analyst Decision
Strong Buy
Buy
Analyst Count
15
2
Target Price
$32.53
$8.38
AVG Volume (30 Days)
18.2M
3.6K
Earning Date
05-07-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$80.88
N/A
Revenue Next Year
$96.18
$318.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.77
$3.36
52 Week High
$46.75
$5.36

Technical Indicators

Market Signals
Indicator
QBTS
MOLN
Relative Strength Index (RSI) 27.59 34.20
Support Level N/A $4.04
Resistance Level $16.29 $4.07
Average True Range (ATR) 0.97 0.27
MACD -0.18 -0.07
Stochastic Oscillator 2.24 0.00

Price Performance

Historical Comparison
QBTS
MOLN

About QBTS D-Wave Quantum Inc.

D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: